DNLI
Price
$21.08
Change
+$1.06 (+5.29%)
Updated
Feb 6 closing price
Capitalization
3.29B
21 days until earnings call
Intraday BUY SELL Signals
TLPPF
Price
$6.84
Change
-$0.16 (-2.29%)
Updated
Feb 6 closing price
Capitalization
2.28B
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs TLPPF

Header iconDNLI vs TLPPF Comparison
Open Charts DNLI vs TLPPFBanner chart's image
Denali Therapeutics
Price$21.08
Change+$1.06 (+5.29%)
Volume$1.65M
Capitalization3.29B
Telix Pharmaceutical
Price$6.84
Change-$0.16 (-2.29%)
Volume$5.07K
Capitalization2.28B
DNLI vs TLPPF Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
TLPPF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. TLPPF commentary
Feb 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and TLPPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 09, 2026
Stock price -- (DNLI: $21.08 vs. TLPPF: $6.84)
Brand notoriety: DNLI and TLPPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 95% vs. TLPPF: 115%
Market capitalization -- DNLI: $3.29B vs. TLPPF: $2.28B
DNLI [@Biotechnology] is valued at $3.29B. TLPPF’s [@Biotechnology] market capitalization is $2.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileTLPPF’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • TLPPF’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNLI and TLPPF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while TLPPF’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • TLPPF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than TLPPF.

Price Growth

DNLI (@Biotechnology) experienced а -3.04% price change this week, while TLPPF (@Biotechnology) price change was -4.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.30%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +31.79%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.29B) has a higher market cap than TLPPF($2.28B). DNLI YTD gains are higher at: 27.680 vs. TLPPF (-11.519). TLPPF has higher annual earnings (EBITDA): 41.7M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. TLPPF (207M). DNLI has less debt than TLPPF: DNLI (44.4M) vs TLPPF (418M). TLPPF has higher revenues than DNLI: TLPPF (638M) vs DNLI (0).
DNLITLPPFDNLI / TLPPF
Capitalization3.29B2.28B144%
EBITDA-534.17M41.7M-1,281%
Gain YTD27.680-11.519-240%
P/E RatioN/A293.58-
Revenue0638M-
Total Cash848M207M410%
Total Debt44.4M418M11%
FUNDAMENTALS RATINGS
DNLI vs TLPPF: Fundamental Ratings
DNLI
TLPPF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
9790
PRICE GROWTH RATING
1..100
4086
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLPPF's Valuation (50) in the null industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that TLPPF’s stock grew somewhat faster than DNLI’s over the last 12 months.

TLPPF's Profit vs Risk Rating (80) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that TLPPF’s stock grew similarly to DNLI’s over the last 12 months.

TLPPF's SMR Rating (90) in the null industry is in the same range as DNLI (97) in the Biotechnology industry. This means that TLPPF’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for TLPPF (86) in the null industry. This means that DNLI’s stock grew somewhat faster than TLPPF’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as TLPPF (100) in the null industry. This means that DNLI’s stock grew similarly to TLPPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLITLPPF
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 20 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 3 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
76%
Aroon
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
TLPPF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAGCX225.425.46
+2.48%
Fidelity Advisor Growth Opps I
MVSSX36.850.82
+2.28%
Victory Integrity Small-Cap Value R6
LGCWX20.670.43
+2.12%
Lord Abbett Global Equity R6
SPGRX22.030.40
+1.85%
DWS Equity Sector Strategy Fund Class S
KGGIX16.780.17
+1.02%
Kopernik Global All-Cap I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with NRIX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+5.29%
NRIX - DNLI
68%
Closely correlated
+5.64%
IMVT - DNLI
64%
Loosely correlated
+12.43%
VRDN - DNLI
63%
Loosely correlated
+0.27%
ARWR - DNLI
63%
Loosely correlated
-0.19%
SYRE - DNLI
62%
Loosely correlated
+6.62%
More

TLPPF and

Correlation & Price change

A.I.dvisor tells us that TLPPF and GLMD have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLPPF and GLMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLPPF
1D Price
Change %
TLPPF100%
-2.21%
GLMD - TLPPF
25%
Poorly correlated
+11.58%
DNLI - TLPPF
24%
Poorly correlated
+5.29%
BEAM - TLPPF
24%
Poorly correlated
+7.24%
RXRX - TLPPF
23%
Poorly correlated
+11.80%
JANX - TLPPF
23%
Poorly correlated
+7.31%
More